Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022

SELL
$38.49 - $76.21 $2.81 Million - $5.56 Million
-72,934 Closed
0 $0
Q1 2022

May 12, 2022

BUY
$58.27 - $118.99 $4.25 Million - $8.68 Million
72,934 New
72,934 $5.3 Million

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $722M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Cqs (Us), LLC Portfolio

Follow Cqs (Us), LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cqs (Us), LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cqs (Us), LLC with notifications on news.